|
|
||||||||||
|
J Am Coll Cardiol, 2004; 43:162-168, doi:10.1016/j.jacc.2003.08.033 © 2004 by the American College of Cardiology Foundation |




* Institut de Cardiologie, Pitié-Salpétrière University Hospital, Paris, France
Department of Haematology, Hospital Lariboisiere, Paris, France
Unite de Recherche Clinique, Hospital Lariboisiere, Paris, France
Manuscript received February 5, 2003; revised manuscript received August 13, 2003, accepted August 25, 2003.
* Reprint requests and correspondence: Dr. Gilles Montalescot, Institut de Cardiologie, Bureau 2-236, Pitié-Salpétrière University Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France.
gilles.montalescot{at}psl.ap-hop-paris.fr
This work will be presented in part at the Scientific Sessions of the American College of Cardiology, Chicago, Illinois, March 2003.
OBJECTIVES: The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in nonST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention.
BACKGROUND: Although thienopyridines and glycoprotein (GP) IIb/IIIa antagonists are often co-prescribed in the context of NSTEMI, the antiplatelet interaction of these agents is poorly described and the superiority of GP IIb/IIIa antagonists above thienopyridine treatment alone is not clear.
METHODS: Thirty-two NSTEMI patients treated with aspirin and enoxaparin were studied using flow cytometry to define parameters of platelet activation with a panel of agonists before clopidogrel, after clopidogrel, and during an eptifibatide infusion following the clopidogrel load.
RESULTS: After platelet activation with adenosine diphosphate, thrombin receptor-activating peptide, or U46-619, relative reductions in conformationally activated GP IIb/IIIa receptor expression (evaluated with PAC-1) of 48%, 43%, and 33%, respectively (all p < 0.0001), were seen with clopidogrel, but further 80%, 78%, and 72% (all p < 0.0001) reductions were seen with eptifibatide. With the same agonists, fibrinogen binding was significantly reduced after clopidogrel by 70%, 64%, and 81% (all p < 0.0001) and again further reduced with eptifibatide by 90%, 95%, and 69% (all p < 0.0001). The total number of GP IIb/IIIa receptors (measured as P2 expression) and P-selectin expression fell after clopidogrel, after ex vivo stimulation with the same agonists; however, both parameters increased slightly during the eptifibatide infusion.
CONCLUSIONS: The activated GP IIb/IIIa expression and fibrinogen binding findings indicate that eptifibatide provides significant potent antiplatelet activity above aspirin and clopidogrel, suggesting additive immediate protection in the treatment of NSTEMI. The P2 and P-selectin findings suggest the possibility of a partial agonist and/or pro-inflammatory effect.
| ||||||||||||||||||||||||
This article has been cited by other articles:
![]() |
D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dudek, A. Dziewierz, B. Chyrchel, L. Polonski, J. Legutko, and J. S. Dubiel Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight) Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A25 - A31. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, Ph. G. Steg, M. Slama, O. Milleron, J.-P. Collet, P. Henry, et al. A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial J. Am. Coll. Cardiol., September 5, 2006; 48(5): 931 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cavallini and F. Chirillo Non-ST-elevation acute coronary syndromes management: a fresh look at glycoprotein IIb/IIIa inhibitors Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K10 - K14. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF] |
||||
![]() |
B. K. Nallamothu, E. R. Bates, J. S. Hochman, C. B. Granger, V. Guetta, R. G. Wilcox, H. D. White, P. W. Armstrong, S. Savonitto, G. Jia, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial Eur. Heart J., August 1, 2005; 26(15): 1506 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF] |
||||
![]() |
T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, January 19, 2005; 293(3): 349 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Schulman Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, October 20, 2004; 292(15): 1875 - 1882. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |